Protein profiling and assessment of amyloid beta levels in plasma in canine refractory epilepsy
Issued Date
2023-01-01
Resource Type
eISSN
22971769
Scopus ID
2-s2.0-85181248927
Journal Title
Frontiers in Veterinary Science
Volume
10
Rights Holder(s)
SCOPUS
Bibliographic Citation
Frontiers in Veterinary Science Vol.10 (2023)
Suggested Citation
Phochantachinda S., Chantong B., Reamtong O., Chatchaisak D. Protein profiling and assessment of amyloid beta levels in plasma in canine refractory epilepsy. Frontiers in Veterinary Science Vol.10 (2023). doi:10.3389/fvets.2023.1258244 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/96347
Title
Protein profiling and assessment of amyloid beta levels in plasma in canine refractory epilepsy
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Introduction: The relationship between epilepsy and cognitive dysfunction has been investigated in canines, and memory impairment was prevalent in dogs with epilepsy. Additionally, canines with epilepsy have greater amyloid-β (Aβ) accumulation and neuronal degeneration than healthy controls. The present study investigated plasma Aβ42 levels and performed proteomic profiling in dogs with refractory epilepsy and healthy dogs. Methods: In total, eight dogs, including four healthy dogs and four dogs with epilepsy, were included in the study. Blood samples were collected to analyze Aβ42 levels and perform proteomic profiling. Changes in the plasma proteomic profiles of dogs were determined by nano liquid chromatography tandem mass spectrometry. Results and discussion: The plasma Aβ42 level was significantly higher in dogs with epilepsy (99 pg/mL) than in healthy dogs (5.9 pg/mL). In total, 155 proteins were identified, and of these, the expression of 40 proteins was altered in epilepsy. Among these proteins, which are linked to neurodegenerative diseases, 10 (25%) were downregulated in dogs with epilepsy, whereas 12 (30%) were upregulated. The expression of the acute phase proteins haptoglobin and α2-macroglobulin significantly differed between the groups. Complement factor H and ceruloplasmin were only detected in epilepsy dogs, suggesting that neuroinflammation plays a role in epileptic seizures. Gelsolin, which is involved in cellular processes and cytoskeletal organization, was only detected in healthy dogs. Gene Ontology annotation revealed that epilepsy can potentially interfere with biological processes, including cellular processes, localization, and responses to stimuli. Seizures compromised key molecular functions, including catalytic activity, molecular function regulation, and binding. Defense/immunity proteins were most significantly modified during the development of epilepsy. In Kyoto Encyclopedia of Genes and Genomes pathway analysis, complement and coagulation cascades were the most relevant signaling pathways affected by seizures. The findings suggested that haptoglobin, ceruloplasmin, α2-macroglobulin, complement factor H, and gelsolin play roles in canine epilepsy and Aβ levels based on proteomic profiling. These proteins could represent diagnostic biomarkers that, after clinical validation, could be used in veterinary practice as well as proteins relevant to disease response pathways. To determine the precise mechanisms underlying these relationships and their implications in canine epilepsy, additional research is required.